| Nov 16 |
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Nov 15 |
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
|
| Nov 15 |
bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results
|
| Nov 15 |
bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...
|
| Nov 14 |
bluebird bio says seeking more cash to achieve cash flow break-even
|
| Nov 14 |
bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 14 |
Earnings Snapshot: bluebird bio reports mixed Q3, Q4 revenue outlook below consensus
|
| Nov 14 |
Bluebird: Q3 Earnings Snapshot
|
| Nov 14 |
bluebird bio GAAP EPS of -$0.31 beats by $0.06, revenue of $10.61M misses by $8.07M
|
